The androgen receptor (AR) is a key factor that regulates the behavior and fate of prostate cancer cells. The AR-regulated network is activated when AR binds enhancer elements and modulates specific enhancer-promoter looping. Kallikrein-related peptidase 3 (KLK3), which codes for prostate specific antigen (PSA) is a well-known AR-regulated gene and its upstream enhancers produce bidirectional enhancer RNAs (eRNAs), termed KLK3e. Here, we demonstrate that KLK3e facilitates the spatial interaction of the KLK3 enhancer and the KLK2 promoter and enhances long-distance KLK2 transcriptional activation. KLK3e carries the core enhancer element derived from the androgen response element III (ARE III) which is required for the interaction of AR and Mediator 1 (Med1). Furthermore, we show that KLK3e processes RNA-dependent enhancer activity depending on the integrity of core enhancer elements. The transcription of KLK3e was detectable and its expression is significantly correlated with KLK3 (R 2 =0.6213, p<5x10 -11 ) and KLK2 (R 2 =0.5893, p<5x10 -10 ) in human prostate tissues. Interestingly, RNAi silencing of KLK3e resulted in a modest negative effect on prostate cancer cell proliferation. Accordingly, we report that an androgen-induced eRNA scaffolds the AR-associated protein complex that modulates chromosomal architecture and selectively enhances AR-dependent gene expression.
Abstract:
The androgen receptor (AR) is a key factor that regulates the behavior and fate of prostate cancer cells. The AR-regulated network is activated when AR binds enhancer elements and modulates specific enhancer-promoter looping. Kallikrein-related peptidase 3 (KLK3), which codes for prostate specific antigen (PSA) is a well-known AR-regulated gene and its upstream enhancers produce bidirectional enhancer RNAs (eRNAs), termed KLK3e . Here, we demonstrate that KLK3e facilitates the spatial interaction of the KLK3 enhancer and the KLK2 promoter and enhances long-distance KLK2 transcriptional activation. KLK3e carries the core enhancer element derived from the androgen response element III (ARE III) which is required for the interaction of AR and Mediator 1 (Med1). Furthermore, we show that KLK3e processes RNA-dependent enhancer activity depending on the integrity of core enhancer elements. The transcription of KLK3e was detectable and its expression is significantly correlated with KLK3 (R 2 =0.6213, p<5x10 -11 ) and KLK2 (R 2 =0.5893, p<5x10 -10 ) in human prostate tissues. Interestingly, RNAi silencing of KLK3e resulted in a modest negative effect on prostate cancer cell proliferation. Accordingly, we report that an androgen-induced eRNA scaffolds the AR-associated protein complex that modulates chromosomal architecture and selectively enhances AR-dependent gene expression.
Significance Statement:
We report that eRNAs, a class of long noncoding RNAs (lncRNAs), participate in the ARdependent looping complex that enhances spatial communication of distal enhancers and target promoters, leading to transcriptional activation events. Furthermore, our data show that KLK3 eRNA (KLK3e) selectively enhances the gene expression of AR-regulated genes, and provide evidence for a positive regulatory loop in which AR-dependent transcription is modulated by an intermediate eRNA.
These findings may translate into improved RNA-based therapy (eRNA suppression) to enhance the durability of androgen deprivation therapy (ADT) and prediction the efficacy of ADT by measuring the enhancer-derived activity (eRNA expression) in prostate tumors.
Introduction:
Androgens and the androgen receptor (AR) play pivotal roles not only in the development of the normal prostate gland but also in the growth and progression of prostate cancer (PCa) (1-4). Androgens exert their biological and physiological effects through activating AR transcriptional activity. AR, a 3 transcription factor, recruits ligand-dependent transcriptional machinery that activates a tissue-specific transcriptional program involved in development and differentiation (4) (5) (6) . In PCa cells, AR occupies numerous gene loci to activate transcripts mediating critical cellular activities, such as energy and metabolism (5) . AR activation and reactivation are essential for PCa development and tumor recurrence (7) .
One unanticipated observation that emerged from multiple global studies of RNA Polymerase II (Pol II) occupancy was that Pol II binds to a large number of intergenic AR-bound enhancers marked by histone H3 lysine 4 mono-methylation (H3K4me1) and lysine 27 acetylation (H3K27ac) and produces enhancer-derived long non-coding RNAs (eRNAs) (8) (9) (10) (11) . While eRNAs are bidirectional and nonpolyadenylated, their induction correlates with the induction of adjacent exon-coding genes (9) . The activity of eRNAs was shown to augment the expression of not only neighboring but also intrachromosomally distant genes to convey enhancer-dependent transcription (12, 13) . Recently, the 5'-GRO-seq data have revealed that sequence-specific transcription factors and eRNA transcripts are required for transfer of full enhancer activity to a target promoter (14) . Moreover, eRNAs have been shown to configure a chromatin state that facilitate transcription factors binding on the target promoters at defined genomic loci (15) .
Mechanistically, eRNAs have been shown to associate with the cohesin complex at estrogen receptor binding sites (ERBSs) and contribute to gene activation by stabilizing estrogen receptor- (ER-)/eRNA-induced enhancer-promoter looping (16, 17) . In addition, ncRNA-activating (ncRNA-a), a class of enhancer-like RNAs, has been shown to interact with the Mediator complex that enhances transcription in a cis-mediated mechanism (18) , highlighting an RNA-dependent functional effect.
Therefore, we hypothesized that eRNAs facilitates spatial communication of enhancers and promoters, thereby enhancing transcriptional activation events. Here, we report that the Kallikrein-related peptidase 3 (KLK3) enhancer, one of the strongest AR-bound enhancers in prostate cancer cells, produces KLK3
eRNA (KLK3e) which impacts androgen-induced gene activation. This work reveals that KLK3e selectively enhances AR-regulated gene expression through its collaboration with the AR-dependent looping complex. Thus, our findings provide evidence for a positive regulatory loop in which the ARregulated network is modulated by an intermediate eRNA.
Results:
The KLK3 enhancer produces enhancer RNA (KLK3e)
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We compiled recently established genomic data sets (19) and showed that the KLK3 enhancer, also defined as the androgen response element III (ARE III) (20) was marked by AR, H3K27ac, and H3K4me1, implying that this region is transcriptionally active (Fig. 1A) . In fact, the transcription of KLK3 eRNA (KLK3e) was demonstrated by GRO-seq data (10) and confirmed by our reverse transcription quantitative polymerase chain reaction (RT-qPCR) analyses in androgen-dependent LNCaP, VCaP and androgen-independent LNCaP-abl cells (21) (Fig. 1B, S1A , S1B). The expression of KLK3e was induced within the first hour of dihydrotestosterone (DHT) exposure and its expression level gradually increased in a time-dependent manner, resembling the expression of mature KLK3 in both LNCaP and VCaP cells; in contrast, while transcription at the KLK3 locus remains active in androgen-independent LNCaP-abl, androgens (DHT) did not stimulate their mRNA expression to a comparable magnitude as those in parental LNCaP cells (Fig. S1B ). Next, we investigated the impact of AR antagonist, bicalutamide on the expression of KLK3e. The expression of KLK3e and KLK3 was induced upon DHT stimulation and blocked by bicalutamide (Fig. S1C ), revealing that ligand-dependent eRNA synthesis takes place in association with target mRNA transcription. Taken together, our findings are consistent with the previous report that there is a high correlation of activity-dependent induction between eRNAs and adjacent coding mRNAs (9) .
Although multiple studies have identified different eRNA species from mammalian enhancers, the precise mapping of eRNAs has not been described. Since eRNAs produced from these intergenic enhancers are low at steady state (9) and estimated at fewer than 100 copies per cell (17), we enriched cellular RNAs by depleting ribosomal RNAs (rRNAs) prior to reverse transcription (RT). PCR primer sets against the antisense (AS1-AS4) and sense (S1-S7) of KLK3e were designed based on the GRO-seq and genomic data sets (10, 19) . As shown in Fig. 1C , the transcription of bidirectional KLK3e as was captured; whereas, no robust DHT-induced transcription was detectable beyond AS4 and S7. We performed primer-extension PCR assay to connect shorter fragments ( Fig. S1D ) and further showed PCR products for the antisense (2230bp) and sense (2170bp) of KLK3e ( Fig. 1C and cDNA sequences available in SI). To distinguish whether the eRNA at KLK3 enhancer are polyadenylated or not, we performed reverse transcription using random hexamer primers and 3' RACE (Poly-T) adapter from the same RNA materials. As shown in S1E, the expression of AS4 and S7 was substantially induced by DHT treatment, suggesting that the poly-A tail was added to the 3'-end of antisense and sense KLK3e.
In contrast, S1 showed less DHT-stimulated expression in the Poly-T priming as compared to random hexamer primed cDNA. These data suggest that this locus produces a mixture of RNA species; some of 5 them are polyadenylated while others may be actively undergoing synthesis of polyadenylation, but we cannot totally exclude the existence of those species without poly-A tails. To detect the size of the mature eRNA at this loci, we customized double DIG-labeled probes using Locked Nucleic Acids (LNA™) (Exiqon). Northern analysis revealed that a major form (~2.5kb) and a minor form (~1.7kb) of sense KLK3e were produced upon DHT induction; whereas no signal was detected at the antisense strand ( Fig. S1F) , suggesting that the expression of antisense strand may be lower than the levels that can be detected by the LNA probe. (Fig. S1F) . Collectively, this suggests that the sense strand (S1-S7)
KLK3e, a ~2.2 kb transcript, is polyadenylated and yields a ~2.5 kb transcript shown in Northern analysis. Although the antisense KLK3e can be polyadenylated and detected by qPCR, its expression may be substantially lower than the sense strand and cannot be detected by Northern analysis under the same experimental settings, indicating that the sense strand KLK3e is the dominate species.
The regulatory function of KLK3e on the Kallikrein Locus
To investigate the potential function of eRNAs in transcriptional regulation, short interfering RNAs (siRNAs) targeting KLK3e (siKLK3e) were designed on the basis of KLK3e mapping. Results obtained from distinct sets of siRNAs against the sense strand of KLK3e showed that siKLK3e specifically targeted sense KLK3e and significantly impeded DHT-induced KLK3 expression in both
LNCaP and VCaP cells but had a minimal impact on LNCaP-abl cells ( Fig. 2B and S2A , B, C, D, and E), consistent with the notion that ligand-activated eRNAs are important for nearby gene activation (13, 17) . Considering that KLK15, 2, and 4 were adjacent to KLK3 and androgen-responsive ( Fig. 2A) , we examined whether KLK3e impacted transcription of these KLKs. Interestingly, knocking down of sense KLK3e significantly inhibited the expression of KLK2; whereas, other KLKs remained unchanged (Fig.   2B ). We also investigated the effect of antisense KLK3e on the regulation of target gene expression.
RNAi silencing of the antisense of KLK3e showed a marginal inhibitory effect on KLK3 and KLK2 gene expression (Fig. S2F) . Despite the presence of bidirectional KLK3e transcription, data from siRNA to KLK3e and Northern analysis showed that the sense strand of KLK3e is the dominant transcript with functional effects on the expression of KLK3 and distant KLK2. Thus, we chose the sense KLK3e and continued to study its RNA-dependent enhancer activity.
Since the induction of eRNA is strongly correlated with the enhancer looping to target gene promoters (13, 16, 17) , it is possible that the KLK3 enhancer element is able to interact with the KLK2
promoter. To address this, we utilized the chromosome conformation capture (3C) assay to study the 6 spatial interaction of the KLK3/2 loci. It should be noted that the KLK2 promoter contains an ARE I which shares over 80% sequence homology with the ARE I in the KLK3 promoter (20) . Indeed, DHT induces KLK2 transcription and the interaction between the anchor and fragment D and E by 2~3 fold (Fig. 2C) . Amplified PCR of anchor-fragment D (105bp) and anchor-fragment E (115bp) was confirmed by DNA sequencing (Fig. S2G and H) , suggesting that the KLK3 enhancer interacts with the KLK2 promoter to mediate distal KLK2 gene activation.
To study the mechanism of KLK3e-mediated transcriptional events, we looked for KLK3e interacting partners by asking whether KLK3e interacts with AR, since KLK3e carries the core enhancer element. We conducted AR-directed RNA immunoprecipitation (RIP) coupled with qPCR using primer sets targeting the core enhancer element at 5'end (S1), middle segment (S4) and 3' end (S7) of the sense KLK3e (Fig. 1C) . Our results show a specific DHT-induced interaction between AR and S1 ( Fig. S2I ),
suggesting that AR relies on the core enhancer element of KLK3e. Since Med1 has been shown to directly interact with AR and is involved in the chromosomal interaction of enhancer-promoter looping (22, 23) , we next asked whether Med1 participates in the observed eRNA functions. RIP analysis revealed a strong androgen-stimulated interaction of S1 and Med1 (Fig. S2J ), comparable to the interaction of KLK3e and AR. Conversely, the antisense KLK3e (AS1) exhibited modest interaction with AR and Med1 (Fig. S2K) , implying that the enhancer function of these two KLK3e species is determined by the levels of interaction with the AR-Med1 complex.
To investigate the potential role of KLK3e in the KLK3/2 loci, we next used 3C-qPCR to assess the interaction of the anchor-fragment D/E regions in KLK3e depleted cells. Silencing of KLK3e impaired KLK2 gene expression and the interaction of the KLK2 promoter and the KLK3 enhancer (Fig.   2D ). Suppression of Med1 also substantially reduced the interaction of the KLK3/2 loci (Fig. 2D, S2L ), supporting a pivotal role of Med1 in mediating this long range chromatin looping (18, 22 (Fig. 3C ). In addition, the effect of siKLK3e and siMed1 on the gene expression of KLK2 and Med1 was shown in Fig. S3A . Altogether our data suggest that KLK3e
cooperates with Med1 to enhance KLK2 gene expression. It should be noted that the actions of AR, Med1 and Pol II at the KLK3 promoter were comparable to those at the KLK2 promoter (Fig.S3B, C and D), implying that the regulatory function of KLK3e at the KLK3/2 promoters may act through the same AR-dependent ribonucleoprotein complex.
Interestingly, silencing of KLK3e did not affect the action of AR and Pol II on the KLK3 enhancer ( Fig S3E) , suggesting that the biogenesis of KLK3e takes place after ligand-activated AR was recruited to the enhancer. While depletion of Med1 blocked AR binding and Pol II activation on the KLK3 enhancer, the expression of KLK3e was not significantly affected, implying that residual Med1-associated module may be sufficient for KLK3e production (Fig.S3F) . Collectively, our data show the mechanism by which KLK3e forms a functional complex with AR and Med1 to promote transcription, supporting the findings that transfer of full enhancer activity to a target promoter depends on enhancerbound transcription factors and enhancer-derived RNA transcripts (14) .
The core enhancer element renders KLK3e RNA-dependent enhancer activity.
To validate the enhancer function of KLK3e, we utilized a luciferase reporter assay to quantitatively measure AR transcriptional activity. While inclusion of KLK3e (S1-S7) or flipped (S7-S1) sequences markedly increased KLK2 promoter activity by 4~5 fold, this effect was abolished when ARE III sequences were deleted (S2-S7) ( Fig. 4A ), confirming the importance of the enhancer integrity and their orientational independency (17, 24) .
The expression of the KLK3e from the luciferase reporter was validated by RT-PCR ( Figure   S4A ), indicating that AREs have the capacity to produce eRNAs. We next asked whether the KLK3e transcript alone is adequate for this transcriptional enhancement. For this purpose, we performed a cotransfection study based on reporters together with CMV-driven sense KLK3e constructs. As shown, the full-length (S1-S7) and flipped (S7-S1) KLK3e increased luciferase expression by 2~2.5 fold; whereas, ARE deletion (S2-S7) failed to enhance promoter activity (Fig. 4B ). Furthermore, antisense KLK3e 8 (AS1-AS4) was unable to induce luciferase expression as sense KLK3e (S1-S7) did ( Fig. S4B and C), again arguing that the sense KLK3e is the functional lncRNA rather than the antisense strand. To examine whether AR is required for the action of KLK3e, we conducted experiments in AR-negative COS-7 cells and confirmed that the activity of KLK3e depends on the availability of ligand-activated AR ( Fig. S4D and E) . Altogether, these data show that the core enhancer elements are essential for the enhancer activity of KLK3e and that ectopic KLK3e induces the promoter activity on a luciferase reporter, implying a trans-regulatory activation mediated by KLK3e.
As a complementary approach, we also addressed whether the observed luciferase expression is mediated through endogenous KLK3e. RNAi silencing of KLK3e significantly reduced luciferase activity in the reporters with or without KLK3e insertion ( 
KLK3 eRNA selectively enhances AR-regulated gene expression
To explore the potential effect of KLK3e beyond the KLK locus, we measured the expression of canonical androgen-regulated genes in KLK3e depleted cells. Suppression of KLK3e decreased the expression of NKX3.1, FKBP5 and PLZF; whereas, the expression of TMPRSS2, PDE9A and GUCY1A3 was not affected ( human prostate tumors (25) and showed that the correlation (R 2 ) of KLK3e (S1) with KLK3, KLK2, NKX3.1 and TMPRSS2 was 0.6213 (p<5x10 -11 ), 0.5893 (p<5x10 -10 ), 0.4624 (p<2x10 -7 ) and 0.3787 (p<5x10 -6 ), respectively. In addition, the expression the KLK3 and KLK2 was the most correlated (R 2 =0.8361, p<3x10 -16 ) ( Fig. 5B and S5F ). Collectively, these in vivo data indicate that the transcription of KLK3e was detectable and its presence correlates with KLK3/2 gene expression. We noted less of a correlation between KLK3e expression and those genes in trans, and the correlation was stronger with NKX3.1 than TMPRSS2, consistent with our in vitro data, although these data do not prove a direct effect in vivo of KLK3e on the transcription of these genes. Next, we investigated the biological effect of KLK3e siRNA on LNCaP cells and showed that KLK3e depletion significantly compromised cell growth in the presence and absence of exogenous androgens (Fig. 5C ). While this negative effect is modest, we postulate that suppression of multiple eRNAs produced from distinct enhancer elements may synergetically block AR transcriptional program. Thus, substantial efforts are needed to fully characterize the transcriptional and biological functions of other significant androgen-induced eRNAs in the future.
Discussion
We demonstrate that bidirectional KLK3e was produced from one of the strongest AR-bound enhancers (ARE III) and its expression pattern resemble KLK3 in prostate cancer cell lines (Figure 1,   S1 ), in agreement with the previous report that a high correlation of activity-dependent induction exists between eRNAs and adjacent coding mRNAs (9 5B) . However, we do not completely understand how KLK-associated eRNAs are regulated in castration resistant prostate cancer (CRPC), although it is well-accepted that the ARmediated transcriptional program remains active. This observation can be explained by the activity of other nuclear receptors, since the core sequence of ARE can be also be recognized by glucocorticoid receptor (GR), progesterone receptor (PR), and mineralocorticoid receptor (MR) (27) . More importantly, it has been shown that AR inhibition resulted in GR upregulation in a subset of prostate cancer cells supporting a mechanism of bypassing AR blockade via an alternative nuclear receptor in CRPC (28).
Thus, it is possible that GR, PR or MR may mediate the expression of KLK3e, KLK3 and KLK2, attributing to adaptive or compensatory effects generated during CRPC development.
In view of the regulatory potential of lncRNAs on gene regulation in trans (29) (30) (31) , eRNAs may be part of co-activator complexes and regulatory factors that participate in the transcriptional regulatory network. Although the entire circuitry of AR-dependent genes is unlikely controlled by a single eRNA, presumably, there are more androgen-induced eRNAs, and there could be redundancy in their enhancer activity. It is conceivable that multiple eRNAs produced from distinct enhancer elements tether with their own transcriptional modules that operate simultaneously to initiate an accurate and a rapid transcriptional program. Therefore, we propose that an eRNA may function as a scaffold that guides an AR-associated protein complex to target chromatin and selectively enhances DHT-stimulated transcription either intra-chromosomally (cis activity) or inter-chromosomally (trans activity). This positive regulatory loop may provide new insight into RNA-dependent functional effects on the regulation of lineage-or tissue-specific gene expression.
While androgen-deprivation therapy (ADT) is designed to block the androgen signaling pathway and is the standard treatment for advanced prostate cancer, this study may help us to understand how androgen ADT influences the activity of AR-bound enhancers through altered expression of eRNAs. In addition, the differential eRNA expression patterns observed may be predicative markers of ADT efficacy for individual prostate cancer patients. More importantly, eRNAs may represent new targets that when suppressed may improve the therapeutic durability of ADT.
Experimental Procedures: Chromatin Immunoprecipitation (ChIP) assay
ChIP experiments were performed as previously described (19) Bottom panel: Reporter assays analyses were performed with or without insertion of full-length (S1-S7), flipped (S7-S1) and ARE deleted (S2-S7) of sense KLK3e.
(B) Reporter analysis of co-transfecting the reporter with independent overexpressing vector as indicated.
(C) The effects of siKLK3e (left) or siMed1 (right) on the KLK2 promoter-driven Luciferase activity.
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Luciferase activity was measured in the presence of DHT (10nM) for 24 hrs. All data shown are mean ±S.D. of at least three independent experiments. * p<0.05; firefly luciferase/ Renilla luciferase (FL/RL). 
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Plasmid Constructs for Luciferase Assay
Full-length (S1-S7), flipped (S7-S1), ARE deleted (S2-S7), and antisense (AS1-AS4) of KLK3e were subcloned into pcDNA3 (Invitrogen) using EcoRI and XbaI sites. pGL3-Basic (Promega) was digested with SacI and XhoI and KLK2 promoter (-407~+143) promoter was inserted into these sites.
Additionally, TK promoter sequences from pRL-TK (Promega) were subcloned into pGL3/KLK2 promoter using BglII and HindIII. Full length (S1-S7), flipped (S7-S1) and ARE deleted (S2-S7) KLK3e
were inserted into downstream of SV40 late poly(A) signal of luciferase reporter. Luciferase experiments were conducted in 96-well white plates using Dual-Glo (Promega) according to the manufacturer's protocol.
Northern blot analysis
Northern blot assay was performed using DIG Northern Starter Kit (Roche) with some modifications.
Total RNA was isolated and purified from LNCaP treated with or without DHT (10 nM). 2g or 40g of RNA were subjected to electrophoresis, followed by hybridization using the 10 nM of LNA probes (Exiqon) against KLK3: /5DigN/tcaggaggctcatatcgtaga/3DigN/, actin (Exiqon), sense KLK3e: /5DigN/atgctggatgatgagtggatga/3DigN/ and antisense KLK3e: /5DigN/agtgacctaacatctctgtga/3DigN/.
Cell Proliferation assay
Cell growth was examined using the WST1 assay (Roche) following the manufacturer's protocol.
Briefly, 3,000 LNCaP cells were grown in a 96-well-plate in the RPMI-1640 medium containing 5% C-FBS. After 2-day incubation, cells were transfected with 50 nM of siRNAs to non-silencing control (siCtrl) or KLK3e (siKLK3e). After 24 hours of incubation, cells were treated with ethanol (Veh) or DHT (10nM). Then, the WST1 assay was performed after Day 0-6. 
